TY - JOUR
T1 - In vivo sub-chronic treatment with dichlorvos in young rats promotes synaptic plasticity and learning by a mechanism that involves Acylpeptide Hydrolase instead of acetylcholinesterase inhibition. Correlation with endogenous β-amyloid levels
AU - García-Rojo, Gonzalo
AU - Gámiz, Fernando
AU - Ampuero, Estíbaliz
AU - Rojas-Espina, Daniel
AU - Sandoval, Rodrigo
AU - Rozas, Carlos
AU - Morales, Bernardo
AU - Wyneken, Ursula
AU - Pancetti, Floria
N1 - Publisher Copyright:
© 2017 García-Rojo, Gámiz, Ampuero, Rojas-Espina, Sandoval, Rozas, Morales, Wyneken and Pancetti.
PY - 2017/7/25
Y1 - 2017/7/25
N2 - Acylpeptide hydrolase (APEH) is a serine hydrolase that displays two catalytic activities, acting both as an exopeptidase toward short N-acylated peptides and as an endopeptidase toward oxidized peptides or proteins. It has been demonstrated that this enzyme can degrade monomers, dimers, and trimers of the Aβ1-40 peptide in the conditioned media of neuroblastoma cells. In a previous report, we showed that the specific inhibition of this enzyme by the organophosphate molecule dichlorvos (DDVP) triggers an enhancement of long-term potentiation in rat hippocampal slices. In this study, we demonstrate that the same effect can be accomplished in vivo by sub-chronic treatment of young rats with a low dose of DDVP (0.1 mg/kg). Besides exhibiting a significant enhancement of LTP, the treated animals also showed improvements in parameters of spatial learning and memory. Interestingly, higher doses of DDVP such as 2 mg/kg did not prove to be beneficial for synaptic plasticity or behavior. Due to the fact that at 2 mg/kg we observed inhibition of both APEH and acetylcholinesterase, we interpret that in order to achieve positive effects on the measured parameters only APEH inhibition should be obtained. The treatment with both DDVP doses produced an increase in the endogenous concentration of Aβ1-40, although this was statistically significant only at the dose of 0.1 mg/kg. We propose that APEH represents an interesting pharmacological target for cognitive enhancement, acting through the modulation of the endogenous concentration of Aβ1-40.
AB - Acylpeptide hydrolase (APEH) is a serine hydrolase that displays two catalytic activities, acting both as an exopeptidase toward short N-acylated peptides and as an endopeptidase toward oxidized peptides or proteins. It has been demonstrated that this enzyme can degrade monomers, dimers, and trimers of the Aβ1-40 peptide in the conditioned media of neuroblastoma cells. In a previous report, we showed that the specific inhibition of this enzyme by the organophosphate molecule dichlorvos (DDVP) triggers an enhancement of long-term potentiation in rat hippocampal slices. In this study, we demonstrate that the same effect can be accomplished in vivo by sub-chronic treatment of young rats with a low dose of DDVP (0.1 mg/kg). Besides exhibiting a significant enhancement of LTP, the treated animals also showed improvements in parameters of spatial learning and memory. Interestingly, higher doses of DDVP such as 2 mg/kg did not prove to be beneficial for synaptic plasticity or behavior. Due to the fact that at 2 mg/kg we observed inhibition of both APEH and acetylcholinesterase, we interpret that in order to achieve positive effects on the measured parameters only APEH inhibition should be obtained. The treatment with both DDVP doses produced an increase in the endogenous concentration of Aβ1-40, although this was statistically significant only at the dose of 0.1 mg/kg. We propose that APEH represents an interesting pharmacological target for cognitive enhancement, acting through the modulation of the endogenous concentration of Aβ1-40.
KW - Acetylcholinesterase
KW - Acylpeptide hydrolase
KW - Dichlorvos
KW - Hippocampus
KW - Learning
KW - Synaptic plasticity
UR - http://www.scopus.com/inward/record.url?scp=85025823522&partnerID=8YFLogxK
U2 - 10.3389/fphar.2017.00483
DO - 10.3389/fphar.2017.00483
M3 - Article
AN - SCOPUS:85025823522
SN - 1663-9812
VL - 8
JO - Frontiers in Pharmacology
JF - Frontiers in Pharmacology
IS - JUL
M1 - 483
ER -